reports
- ABGSC Energy Research
- Daniel Vårdal Haugland
- John Olaisen
- Lars Trongaard Brattli
- Martin Mauseth
- Njål Kleiven
- Stian Wibstad
- ABGSC Renewable Energy Research
- Åsne Holsen
- Daniel Vårdal Haugland
- ABGSC Energy Research
- Daniel Vårdal Haugland
- John Olaisen
- Lars Trongaard Brattli
- Martin Mauseth
- Njål Kleiven
- Stian Wibstad
- ABGSC Renewable Energy Research
- Åsne Holsen
- Daniel Vårdal Haugland
- ABGSC Energy Research
- Daniel Vårdal Haugland
- John Olaisen
- Lars Trongaard Brattli
- Martin Mauseth
- Njål Kleiven
- Stian Wibstad
- ABGSC Renewable Energy Research
- Åsne Holsen
- Daniel Vårdal Haugland
- ABGSC Energy Research
- Daniel Vårdal Haugland
- John Olaisen
- Lars Trongaard Brattli
- Martin Mauseth
- Njål Kleiven
- Stian Wibstad
- ABGSC Renewable Energy Research
- Åsne Holsen
- Daniel Vårdal Haugland
- John Olaisen
ORSTED ORSTED
AFK ARENDALS FOSSEKOMPANI
HEX HEXAGON COMPOSITES ASA
NEL NEL ASA
SSO SCATEC ASA
EOLU B EOLUS VIND AB
FKRFT FJORDKRAFT HOLDING ASA
CADLR CADELER
A2QKGG HEXAGON PURUS
ZAP ZAPTEC
VWS VESTAS WIND SYSTEMS
NIBE B NIBE INDUSTRIER AB
TOM TOMRA SYSTEMS ASA
ITECH I-TECH AB
IWS-NO INTEGRATED WIND SOLUTIONS
- ABGSC Renewable Energy Research
- Åsne Holsen
- Daniel Vårdal Haugland
- John Olaisen
ORSTED ORSTED
AFK ARENDALS FOSSEKOMPANI
HEX HEXAGON COMPOSITES ASA
NEL NEL ASA
SSO SCATEC ASA
EOLU B EOLUS VIND AB
FKRFT FJORDKRAFT HOLDING ASA
CADLR CADELER
A2QKGG HEXAGON PURUS
ZAP ZAPTEC
VWS VESTAS WIND SYSTEMS
NIBE B NIBE INDUSTRIER AB
TOM TOMRA SYSTEMS ASA
ITECH I-TECH AB
IWS-NO INTEGRATED WIND SOLUTIONS
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- ABGSC Renewable Energy Research
- Åsne Holsen
- Daniel Vårdal Haugland
- Thomas Mordelle
- ABGSC Renewable Energy Research
- Åsne Holsen
- Daniel Vårdal Haugland
- ABGSC Renewable Energy Research
- Åsne Holsen
- Daniel Vårdal Haugland
- Oscar Haffen Lamm
Vicore Pharma: KOL & Mgmt Takeaways, buloxibutid's IPF positioning upd...
Yesterday, we attended a lunch organized by Vicore’s management with Dr. Francesco Bonella, an IPF specialist based in Germany who has advised companies such as Boehringer Ingelheim, Roche, Galapagos, and BMS in the development of compounds for rare lung diseases. Dr. Bonella is also an investigato
- Oscar Haffen Lamm
Vicore Pharma: Phase 2b ASPIRE trial making good progress
Vicore Pharma reported its Q1'25 results which mainly focused on balance sheet items and a recap of corporate achievements for the quarter, with notably i) a cash position at SEK1,049m, and ii) opex stable at SEK91.5m (vs SEK99.3m). We are encouraged to see the good progress in the phase 2b ASPIRE
- ABGSC Healthcare Research
- Alexander Krämer
- Martin Huseby Karlsen
Nel (Sell, TP: NOK1.50) - In hope they trust
Q1 revenue missed consensus by 29% and our estimate by 38%. Despite industry-wide challenges, Nel remains optimistic on new orders – although it last booked a sizeable order in late-2022. On the positive side, cash of NOK2.1bn provides investors with decent time optionality awaiting a better market (we do not expect a liquidity injection), added to which it has a good technology track record and know-how. We reiterate our SELL and NOK1.5 target price.
- ABGSC Renewable Energy Research
- Åsne Holsen
- Daniel Vårdal Haugland
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.